Intracranial metastasis in Ewing's sarcoma

Baid, Babu Lal; Tanwar, Rajendra Kumar; De, Sajal; Kotwal, Prakash; Rath, G.K.; Karak, Prasanta; Kochupillai, V.

doi:10.1007/bf02760915

Cited by 7 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that Ewing sarcoma and osteosarcomas represent 12% and 6%, respectively, of sarcoma with BM. BM occurrence for these subtypes have previously been reported between 32% and 56% .…”

Section: Discussionmentioning

confidence: 92%

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

et al. 2018

View full text Add to dashboard Cite

The incidence of brain and meningeal metastasis in bone and soft tissue sarcomas is estimated between 1% and 8%. Published data are derived from small retrospective case series, often in the pediatric population. A prognostic index is important to guide both clinical decision-making and outcomes research, but one such is lacking for adult sarcoma patients with brain metastases. The current study describes brain metastasis in a large cohort of sarcoma patients. This study, conducted within the French Sarcoma Group, describes the natural history of sarcoma brain metastasis and enables the proposal of strategic recommendations for subsequent clinical trials and for the management of such patients.

show abstract

“…We found that Ewing sarcoma and osteosarcomas represent 12% and 6%, respectively, of sarcoma with BM. BM occurrence for these subtypes have previously been reported between 32% and 56% .…”

Section: Discussionmentioning

confidence: 92%

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Ewing's sarcoma is commonly seen in young adults and has a slight male predominance [29–31]. Up to 80% of patients have subclinical metastases at time of presentation [29].…”

Section: Resultsmentioning

confidence: 99%

“…Up to 80% of patients have subclinical metastases at time of presentation [29]. It comprises about 10% of primary malignant bone tumors and, like osteosarcoma, the lungs and distant skeletal tissues are common metastatic sites [31]. CNS metastases have been reported in 32–56% of cases, frequently a result of direct extension of bony metastases in close proximity, with BM making up <1.8% of cases [32].…”

Section: Resultsmentioning

confidence: 99%

“…CNS metastases have been reported in 32–56% of cases, frequently a result of direct extension of bony metastases in close proximity, with BM making up <1.8% of cases [32]. Extremity tumors generally have better prognosis than axial skeleton primaries, which are arduous to completely excise [31–33]. BM usually appears as part of systemic disease, with more than 85% having lung involvement [33].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Brain Metastasis in Bone and Soft Tissue Cancers: A Review of Incidence, Interventions, and Outcomes

Shweikeh

Bukavina

Saeed

et al. 2014

Sarcoma

View full text Add to dashboard Cite

Bone and soft tissue malignancies account for a small portion of brain metastases. In this review, we characterize their incidence, treatments, and prognosis. Most of the data in the literature is based on case reports and small case series. Less than 5% of brain metastases are from bone and soft tissue sarcomas, occurring most commonly in Ewing's sarcoma, malignant fibrous tumors, and osteosarcoma. Mean interval from initial cancer diagnosis to brain metastasis is in the range of 20–30 months, with most being detected before 24 months (osteosarcoma, Ewing sarcoma, chordoma, angiosarcoma, and rhabdomyosarcoma), some at 24–36 months (malignant fibrous tumors, malignant peripheral nerve sheath tumors, and alveolar soft part sarcoma), and a few after 36 months (chondrosarcoma and liposarcoma). Overall mean survival ranges between 7 and 16 months, with the majority surviving < 12 months (Ewing's sarcoma, liposarcoma, malignant fibrous tumors, malignant peripheral nerve sheath tumors, angiosarcoma and chordomas). Management is heterogeneous involving surgery, radiosurgery, radiotherapy, and chemotherapy. While a survival advantage may exist for those given aggressive treatment involving surgical resection, such patients tended to have a favorable preoperative performance status and minimal systemic disease.

show abstract